TEFLARO is also indicated for the treatment of CABP
caused by susceptible bacterial isolates of the following Gram-positive and Gram-negative microorganisms: Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only), Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli.
A procedure plagued by complication rates, figures show that post-surgery complications have been reported in as high as 15 to 25 per cent of cases of CABP
circa 1898] in Folder 22: Recommendations for Charles Austin Beard, DC 10, CABP
In fact, nearly one-quarter of surveyed physicians indicate prescribing ceftaroline for CABP
due to MRSA, and about 10 percent have used the drug for NP in the past 12 months.
The Pharmacor advisory service entitled Community-Acquired Bacterial Pneumonia finds that the CABP
antibiotic market will experience modest growth over the next decade, increasing from approximately $1 billion in 2011 to more than $1.
FDA in October 2010 for the treatment of adults with CABP
and ABSSSI due to designated susceptible pathogens.
Nabriva is establishing its US office and clinical development team in Philadelphia and is focussed on advancing lefamulin to phase 3 trials, for an initial indication in CABP
Mark Leuchtenberger, Chief Executive Officer of Rib-X said, "The need for antibiotics that safely treat a broader spectrum of infections, not to mention those which have shown resistance to linezolid, is growing and radezolid has thus far succeeded in addressing a diverse set of challenges in ABSSSI and CABP
What factors are driving the market for CABP
In the United States, France, Germany, Italy, Spain, the United Kingdom and Japan, radezolid's key competitor in the CABP
drug market through 2020 will be Pfizer's Zyvox.
Food and Drug Administration for the phase 3 trials planned in ABSSSI and CABP
The goal of Solitaire-IV is to provide evidence of safety and efficacy of an IV-to-oral step down regimen that we believe will provide clinicians and their patients a better therapeutic option to treat CABP
," said Prabhavathi Fernandes, Ph.